Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 1/2015

01-01-2015 | Erratum

Erratum to: Differences in expression of proliferation-associated genes and RANKL across the menstrual cycle in estrogen receptor-positive primary breast cancer

Authors: Ben P. Haynes, Giuseppe Viale, Viviana Galimberti, Nicole Rotmensz, Bianca Gibelli, Ian E. Smith, Mitch Dowsett

Published in: Breast Cancer Research and Treatment | Issue 1/2015

Login to get access

Excerpt

In the original publication of the article, Fig. 3 was mislabelled as Fig. 4 and vice-versa. This means that references to these figures in the text are the wrong way round. …
Metadata
Title
Erratum to: Differences in expression of proliferation-associated genes and RANKL across the menstrual cycle in estrogen receptor-positive primary breast cancer
Authors
Ben P. Haynes
Giuseppe Viale
Viviana Galimberti
Nicole Rotmensz
Bianca Gibelli
Ian E. Smith
Mitch Dowsett
Publication date
01-01-2015
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2015
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-014-3210-5

Other articles of this Issue 1/2015

Breast Cancer Research and Treatment 1/2015 Go to the issue

Epidemiology

Immunoassay and Nb2 lymphoma bioassay prolactin levels and mammographic density in premenopausal and postmenopausal women the Nurses’ Health Studies

Clinical trial

Effects of the BEAT Cancer physical activity behavior change intervention on physical activity, aerobic fitness, and quality of life in breast cancer survivors: a multicenter randomized controlled trial

Review

HER2-family signalling mechanisms, clinical implications and targeting in breast cancer

Epidemiology

Toward the breast screening balance sheet: cumulative risk of false positives for annual versus biennial mammograms commencing at age 40 or 50

Preclinical study

A genetic variant at 12p11 significantly modifies breast cancer risk in a genetically homogenous island population

Epidemiology

Pregnancy-associated breast cancer in women from Shanghai: risk and prognosis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits